Palomar (NASDAQ:PLMR) Insider Sells $46,497.24 in Stock

Palomar Holdings, Inc. (NASDAQ:PLMR) insider Jonathan Knutzen sold 381 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $122.04, for a total transaction of $46,497.24. Following the sale, the insider owned 25,658 shares in the company, valued at $3,131,302.32. This trade represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Jonathan Knutzen also recently made the following trade(s):

• On Thursday, January 29th, Jonathan Knutzen sold 444 shares of Palomar stock. The shares were sold at an average price of $122.04, for a total value of $54,185.76.
• On Thursday, January 29th, Jonathan Knutzen sold 444 shares of Palomar stock. The shares were sold at an average price of $122.04, for a total value of $54,185.76.
• On Saturday, January 31st, Jonathan Knutzen sold 290 shares of Palomar stock. The shares were sold at an average price of $121.74, for a total value of $35,304.60.
• On Wednesday, January 28th, Jonathan Knutzen sold 1,535 shares of Palomar stock. The stock was sold at an average price of $119.88, for a total value of $184,015.80.
• On Tuesday, November 18th, Jonathan Knutzen sold 281 shares of Palomar stock. The shares were sold at an average price of $128.84, for a total transaction of $36,204.04.

Palomar Price Performance

Shares of PLMR traded up $0.63 during mid-day trading on Monday, hitting $124.22. The company’s stock had a trading volume of 240,836 shares, compared to its average volume of 180,129. The firm has a 50-day moving average price of $127.67 and a 200 day moving average price of $123.57. Palomar Holdings, Inc. has a fifty-two week low of $104.47 and a fifty-two week high of $175.85. The stock has a market capitalization of $3.29 billion, a price-to-earnings ratio of 19.38 and a beta of 0.44.

Palomar (NASDAQ:PLMR) last released its quarterly earnings data on Thursday, November 6th. The company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.56 by $0.45. Palomar had a return on equity of 21.93% and a net margin of 22.59%.The business had revenue of $244.66 million during the quarter, compared to analyst estimates of $207.98 million. During the same period last year, the company posted $1.23 EPS. As a group, equities analysts anticipate that Palomar Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Trending Headlines about Palomar

Here are the key news stories impacting Palomar this week:

• Positive Sentiment: Palomar closed the acquisition of The Gray Casualty & Surety Company, expanding its surety capabilities and product mix — a strategic tuck?in that can add premium, diversify risk exposure and support growth in specialty lines. BCP Completes Sale of The Gray Casualty & Surety Company
• Neutral Sentiment: Palomar will report Q4 and full?year 2025 results after the close on Feb 11, 2026, with a conference call Feb 12 — an event that typically drives short?term volume and volatility as investors update estimates and listen for management commentary on reserve development, underwriting margin, and growth. Earnings Release & Conference Call
• Negative Sentiment: Multiple insiders (including the CEO, President, CFO and other senior executives) sold shares on Jan. 29 and Jan. 31, reducing positions by low-single-digit percentages in many cases. Heavy insider selling can signal liquidity taking or tax/comp planning, but it may concern some investors about insider confidence or timing ahead of earnings. Representative coverage of recent insider sales is here. CEO Sells Stock (Example)

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Keefe, Bruyette & Woods boosted their target price on shares of Palomar from $170.00 to $171.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 6th. JPMorgan Chase & Co. upped their price objective on shares of Palomar from $145.00 to $155.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. Wall Street Zen raised Palomar from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Finally, Weiss Ratings upgraded Palomar from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, January 14th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $159.50.

Institutional Trading of Palomar

Hedge funds have recently added to or reduced their stakes in the business. Salomon & Ludwin LLC bought a new position in shares of Palomar during the 3rd quarter worth about $25,000. Richardson Financial Services Inc. lifted its stake in Palomar by 210.0% during the third quarter. Richardson Financial Services Inc. now owns 217 shares of the company’s stock worth $25,000 after purchasing an additional 147 shares during the period. Allworth Financial LP boosted its holdings in Palomar by 1,970.0% during the second quarter. Allworth Financial LP now owns 207 shares of the company’s stock valued at $32,000 after purchasing an additional 197 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Palomar in the 4th quarter valued at approximately $32,000. Finally, Clearstead Advisors LLC raised its holdings in shares of Palomar by 31.0% in the 3rd quarter. Clearstead Advisors LLC now owns 397 shares of the company’s stock worth $46,000 after buying an additional 94 shares in the last quarter. Institutional investors own 90.25% of the company’s stock.

About Palomar

Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.

In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.